FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced on May 4, 2026 the release of the first cGMP batch of its investigational drug product CYWC628 to support a Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).

The batch was manufactured under cGMP and passed required safety and quality testing, enabling clinical use and positioning the company to begin patient enrollment for safety, tolerability, and preliminary efficacy evaluation.

Positive

• First cGMP batch released for CYWC628
• Passed required safety and quality testing, enabling clinical use
• Positions company to begin enrollment in Phase 1/2 DFU trial
• Platform validation step for fibroblast-based therapeutic approach

Negative

• CYWC628 is investigational; efficacy and safety remain unproven until trial results
• No clinical outcomes or timelines disclosed for enrollment completion

News Market Reaction – FBLG

-5.48% 2.1x vol

11 alerts

-5.48% Session close to close

+8.3% Peak Tracked

-19.1% Trough Tracked

$6.63M Market Cap

2.1x Rel. Volume

In the May 4 session, FBLG declined 5.48%, reflecting a notable negative market reaction. Argus tracked a peak move of +8.3% during that session. Argus tracked a trough of -19.1% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.5% in the session following this news. A negative reaction despite operational pr...

Analysis

The stock moved -5.5% in the session following this news. A negative reaction despite operational progress would fit the mixed pattern seen around past clinical headlines, where two of four prior events saw declines despite positive updates. With shares already trading well below the 200‑day MA of $7.35 and recent filings highlighting ongoing net losses and going‑concern risks, dilution and financing overhang could weigh on sentiment even as CYWC628 advances into its Phase 1/2 DFU trial.

Key Figures

Patent portfolio: 270+ patents Trial phase: Phase 1/2

2 metrics

Patent portfolio 270+ patents Issued and pending patents mentioned for FibroBiologics

Trial phase Phase 1/2 CYWC628 diabetic foot ulcer clinical trial stage

Previous Clinical trial Reports

4 past events · Latest: Mar 31 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 31	Clinical manufacturing update	Positive	+0.8%	Completion of first CYWC628 batch manufacturing for planned first‑in‑human trial.
Mar 05	Trial site onboarding	Positive	+11.6%	Completed site onboarding for Phase 1/2 CYWC628 DFU clinical trial across APAC.
Dec 31	IND filing	Positive	-7.0%	Filed Phase 1/2 IND with FDA for CYPS317 in moderate to severe psoriasis.
Nov 20	Ethics approval	Positive	-5.8%	Received Australian HREC approval for Phase 1/2 CYWC628 DFU trial with planned enrollment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial updates for FBLG have produced mixed reactions, with two positive and two negative moves around past announcements.

Recent Company History

Recent history for FibroBiologics centers on advancing fibroblast-based therapies into the clinic. Prior clinical trial news covered HREC approval and planned enrollment for CYWC628 in diabetic foot ulcers, site onboarding, and successful manufacturing under FDA cGMP. An IND filing for CYPS317 in psoriasis broadened the pipeline. Today’s announcement fits this sequence, marking progression from manufacturing completion to actual drug product release for a Phase 1/2 DFU study.

Key Terms

fibroblast-based therapy, diabetic foot ulcers, DFUs, current Good Manufacturing Practices (cGMP), +2 more

6 terms

fibroblast-based therapy medical

"CYWC628 is an investigational fibroblast-based therapy designed to address DFUs"

Fibroblast-based therapy uses living fibroblast cells — the body’s natural ‘repair crew’ that builds connective tissue and scars — to restore, regenerate, or remodel damaged skin, organs, or tissues. For investors, it matters because these treatments require clinical proof, durable manufacturing and regulatory approval like any advanced cell therapy, and if successful can address large markets in wound care, cosmetic medicine, or chronic conditions, making them high-risk, potentially high-reward opportunities.

diabetic foot ulcers medical

"clinical trial in patients with diabetic foot ulcers (DFUs)"

A diabetic foot ulcer is an open sore or wound on the foot that occurs when high blood sugar and nerve damage prevent normal healing, much like a small pothole that keeps widening because the road can’t be properly repaired. It matters to investors because these wounds drive demand for treatments, medical devices, wound-care drugs and hospital services, and they carry risks of infection and amputation that can shape healthcare costs, reimbursement decisions and clinical trial opportunities.

DFUs medical

"diabetic foot ulcers (DFUs). The CYWC628 drug product was manufactured"

DFUs stands for diabetic foot ulcers, which are open sores or wounds that occur on the feet of people with diabetes when nerve damage and poor blood flow prevent normal healing. For investors, DFUs matter because they represent a sizable, growing market for treatments, devices and diagnostic tools; a successful therapy can act like a more effective repair kit for a worn machine, reducing repeat procedures, hospital stays and long-term costs, and thereby driving sales and reimbursement interest.

current Good Manufacturing Practices (cGMP) regulatory

"manufactured in accordance with the U.S. Food and Drug Administration’s current Good Manufacturing Practices (cGMP)"

Current Good Manufacturing Practices (cGMP) are a set of required quality rules and procedures that companies must follow when making drugs, medical devices, or related products to ensure they are safe, pure, and consistent—think of them as a strict recipe and checklist for production. Investors care because failure to meet these standards can halt product approvals, trigger recalls, increase costs, and damage reputation, all of which directly affect a company’s revenue and valuation.

cGMP regulatory

"completion of manufacturing of the first cGMP batch of CYWC628"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

Phase 1/2 clinical trial medical

"to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers"

A phase 1/2 clinical trial is an early human study that combines first-in-people safety and dosing checks (phase 1) with an initial look at whether the treatment appears to work (phase 2). Think of it as a short test drive where researchers both confirm the product won’t cause serious harm and gather early signs it could be effective; for investors, successful results reduce risk and can unlock value-creating milestones like larger trials or regulatory discussions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the first batch of its CYWC628 drug product to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).

The CYWC628 drug product was manufactured in accordance with the U.S. Food and Drug Administration’s current Good Manufacturing Practices (cGMP) and has successfully passed all required safety and quality testing, enabling its release for clinical use. This milestone follows the Company’s recent completion of manufacturing of the first cGMP batch of CYWC628.

CYWC628 is an investigational fibroblast-based therapy designed to address DFUs, a chronic condition affecting millions of patients worldwide with limited effective long-term treatment options.

The Phase 1/2 clinical trial is evaluating the safety, tolerability, and preliminary efficacy of CYWC628 in patients with DFUs.

“With the first batch of the CYWC628 drug product released, we are now positioned to begin enrolling patients in our Phase 1/2 DFU trial,” said Pete O’Heeron, Founder and CEO of FibroBiologics. “This milestone allows us to begin the process of generating the data needed to evaluate safety, tolerability, and efficacy in DFUs. These initial results will be important in shaping the commercial path forward for CYWC628 and further validating our fibroblast-based platform.”

For more information, please visit FibroBiologics’ website or email FibroBiologics at info@fibrobiologics.com.  

Cautionary Statement Regarding Forward-Looking Statements 

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning indications of interest, plans for, and the anticipated timing of the initiation and completion of, FibroBiologics’ clinical trials, and the robustness, progress, timing, and momentum of FibroBiologics’ research and development program. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) the ability of FibroBiologics to successfully prosecute its patent applications; (e) FibroBiologics’ ability to manufacture its product candidates; and (f) FibroBiologics’ ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. 

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

What did FibroBiologics (FBLG) announce on May 4, 2026 about CYWC628?

They announced release of the first cGMP batch of CYWC628 for clinical use. According to the company, the batch passed required safety and quality testing and will support the Phase 1/2 diabetic foot ulcer trial and enable patient enrollment.

What is the goal of the Phase 1/2 diabetic foot ulcer trial for CYWC628 (FBLG)?

The trial will evaluate safety, tolerability, and preliminary efficacy of CYWC628 in DFU patients. According to the company, these initial data will inform next steps and help shape the potential commercial path for CYWC628.

Has CYWC628 manufacturing met regulatory manufacturing standards for clinical use?

Yes, the first batch was manufactured in accordance with cGMP and released after testing. According to the company, the batch successfully passed all required safety and quality testing enabling clinical release.

Does the CYWC628 announcement mean FibroBiologics (FBLG) will immediately enroll patients?

The company said the release positions them to begin enrolling patients for the Phase 1/2 DFU trial. According to the company, the released drug product enables the start of the enrollment process but no enrollment dates were provided.

Where can investors find more information about FibroBiologics CYWC628 and the DFU trial?

Investors can visit FibroBiologics’ website or contact their investor email for details. According to the company, additional trial and contact information is available on the company website and via info@fibrobiologics.com.